Expertise in
2
conditions

Gian M. Pica

Chambery, FR 
Expertise in
2
conditions
Chambery, FR 

Overview

Gian Pica practices practicing medicine in Chambery, France.

Mr. Pica is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

He is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Chambery, France
Other Locations
Lyon, France
Hôpital St Louis, APHP
Paris, France
Nice, France
Pierre-la-treiche, France
CHU Grenoble Alpes
Grenoble, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2026
Intervention Type: Drug
Study Drug: Valemetostat tosylate
Study Phase: Phase 2
View 1 Less Clinical Trial

28 Total Publications

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
Journal: British journal of haematology
Published: May 05, 2026

Frequently Asked Questions about Gian M. Pica

Is Gian M. Pica a top-rated expert for Follicular Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Gian M. Pica is classified as an Advanced expert for Follicular Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gian M. Pica participate in research or clinical trials?

Yes. Gian M. Pica has published 28 articles and abstracts on conditions like Follicular Lymphoma. You can view a list of Gian M. Pica's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pica's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile